MedWatch

Japanese ALK study will follow European model

The inspiration for the clinical trials initiated by ALK’s partner company Torii comes from ALK’s own trials in Europe, reveals the CEO of the Danish company.

Foto: ALK-Abelló/PR

Torii has gathered a great deal of inspiration from its Danish partner ALK-Abello in designing the phase 2/3 studies the Japanese company initiated Tuesday.

“It not only looks like them, it is an exact copy of the studies we are running in Europe, because there are two primary end-points in the study in order to get as broad an indication as possible. One arm focuses on hay fever and the other one asthma, and of course it is important, to a Japanese company as well as a European one, to get as broad an indication area as possible,” CEO of ALK, Jens Bager, tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier